The Medicines Company challenges again US PTO's Angiomax patent decision
This article was originally published in Scrip
Executive Summary
The Medicines Company has filed in the US a new lawsuit against the US Patent and Trademark Office (PTO), challenging that office's most recent decision denying a patent term extension (PTE) for the direct thrombin inhibitor, Angiomax (bivalirudin). The firm seeks a ruling that the PTE was submitted on time.